| abstract |
Disclosed herein are methods of treating cardiovascular risk in diabetic patients using a pharmaceutically acceptable form of (Z)-6-((2S,4S,5R)-2-(2-chlorophenyl)-4-(2- hydroxyphenyl)-1,3-dioxan-5-yl)hex-4-enoic acid in combination with a pharmaceutically acceptable form of a P2Y12 inhibitor. |